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Letters
Unsaturated Fatty Acids
to Improve
Cardiorespiratory
Fitness in Patients With
Obesity and HFpEF
The UFA-Preserved Pilot Study
Heart failure with preserved ejection fraction
(HFpEF) and obesity are 2 common and often coex-
isting conditions that reduce cardiorespiratory fitness
(CRF) (1,2).
Intake of unsaturated fatty acids (UFAs), which
consist of monounsaturated fatty acids (MUFAs) and
polyunsaturated fatty acids (PUFAs), has recently
been associated with favorable CRF, body composi-
tion, and cardiac diastolic function in patients with
obesity and HFpEF (3). A high UFA diet also pre-
vented weight gain and cardiac diastolic dysfunction
(3) in a mouse model of Western diet-induced cardiac
dysfunction (4), despite similar total caloric and total
fats intake. However, the feasibility of a dietary
intervention aimed at increasing daily UFA intake in a
prospective trial is required in this population to test
its potential efficacy in a large randomized controlled
trial.
We hypothesized that a 12-week dietary interven-
tion aimed at increasing UFA consumption was
feasible in patients with obesity and HFpEF, and
would result in increased consumption of UFAs at
12 weeks (primary endpoint), as assessed by both
dietary recall and biomarkers. To test this hypothesis,
we performed a proof-of-concept trial and enrolled 9
patients with obesity, symptomatic HFpEF (i.e.,
dyspnea, fatigue), and reduced CRF (<80% of pre-
dicted) measured with maximal cardiopulmonary
exercise testing, in a single-arm dietary intervention.
All study participants provided written consent
(NCT03310099).
Dietary intervention consisted of an individual-
ized, in-person meeting with a dietitian at baseline
and every 4 weeks thereafter, with a weekly tele-
phone call to support dietary adherence. Dietary
intervention was aimed at consuming a recom-
mended daily amount (or more, without upper limit
for consumption) of UFA-rich foods: extra-virgin
olive oil (54 g), canola oil (54 g), unsalted or
lightly salted mixed dry tree nuts (walnuts, hazel-
nuts, almonds, pecans), and peanuts (28 g), without
providing recommendations on caloric intake. In
patients who could not consume the recommended
foods for personal and/or cultural preferences, the
following foods were recommended: unsalted mixed
seeds (28 g), Hass avocado (50 g), and fatty fish
(salmon, tuna, trout, mackerel, sardines) (170 g). We
provided $100 of financial support to purchase the
recommended UFA-rich foods at baseline and 12-
week visits, as well as $50 at 4- and 8-week visits.
At each visit, a standardized 5-pass, 24-h dietary
recall (3) was administered by a dietitian and non-
fasting plasma UFA (oleic acid [MUFA], a-linolenic
acid, and linoleic acid [PUFA]) levels were measured
(Salveo Diagnostics Inc., Henrico, Virginia). We also
measured exercise time, peak oxygen consumption
(VO2) and peak oxygen (O2) pulse at baseline and
at 12 weeks using a metabolic cart interfaced
with a treadmill using a conservative ramping
protocol. Physical activity was assessed using
the International Physical Activity Questionnaire-
short version (IPAQ) to calculate the cumulative
metabolic equivalent of task-minutes per week
(MET-min/week). The Shapiro-Wilk test was used to
assess deviation from a Gaussian distribution with
paired Student’s t-tests and Pearson’s rank test
with mean  SD used to examine changes between
baseline and 12 weeks for normally distributed
variables. Wilcoxon’s test and Spearman’s rank test
with median and interquartile ranges were used to
compare abnormally distributed variables, respec-
tively. Statistical analysis was performed using SPSS
version 24.0 (IBM, Armonk, New York).
Of 9 patients (6 African American) enrolled, 5 were
women; mean age was 54  5 years. All patients had
arterial hypertension, and 5 had type 2 diabetes mel-
litus. Baseline left ventricular EF, N-terminal pro–
brain natriuretic peptide, E/e0 ratio, and left atrial
volumewere 584%, 29 pg/ml (range 17.5 to 54 pg/ml),
8.7  2.9, and 57.9  29.7 ml/m2, respectively. Base-
line peak VO2 was 16.3  5.9 ml/kg1/min1 or 53  12%
of predicted according to age, sex, height, and ideal
body weight. Baseline exercise time and O2 pulse
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were 10.7  3.2 min and 12.8  4.8 ml/beat,
respectively.
After 12 weeks, patients reported a significant in-
crease in the proportion of daily calories derived from
dietary UFAs and demonstrated an increase in plasma
UFA biomarkers (Figure 1A). In addition to increased
UFA consumption, we observed a significant increase
in proportion of calories from total fat consumption
(p ¼ 0.007), but not a proportion of calories from
saturated fatty acids, protein, total calories and mil-
ligrams of sodium intake (all p > 0.05). We found a
significant reduction in the proportion of calories
from total carbohydrates (p ¼ 0.011) and fructose (p ¼
0.02).
Baseline plasma UFAs, MUFAs, and PUFAs were
positively associated with peak VO2 (R ¼ þ0.79; p ¼
0.036; R ¼ þ0.75; p ¼ 0.052; R ¼ þ0.79; p ¼ 0.036,
respectively) and O2 pulse (R ¼ þ0.86; p ¼ 0.014;
R ¼ þ0.89; p ¼ 0.007; R ¼ þ0.86; p ¼ 0.014, respec-
tively). After 12 weeks of UFA supplementation, we
observed a significant improvement in exercise time
and O2 pulse (Figure 1B) with a trend toward a sig-
nificant increase in peak VO2 (p ¼ 0.069), without
significant changes in the respiratory exchange ratio
(1.09  0.09 to 1.07  0.11; p ¼ 0.44), body mass index
(40.0 to 40.2 kg/m2; p ¼ 0.21) or IPAQ-estimated
physical activity (1,155 to 1,030 MET-min/wk; p ¼
0.67). Changes in peak VO2 tended to associate with
changes in plasma UFAs (R ¼ þ0.71; p ¼ 0.071),
MUFAs (R ¼ þ0.75; p ¼ 0.052), and PUFAs (R ¼ þ0.71;
p ¼ 0.071), although the associations did not reach
statistical significance (p < 0.05).
Although limited by the small sample size and
single-arm intervention, for the first time, we showed
that a dietary intervention aimed at increasing UFA
consumption was feasible and had the potential to
improve CRF in patients with severe obesity and
HFpEF. Larger randomized controlled trials to test
the efficacy of UFA supplementation on CRF and
clinical outcomes, as well as understanding the
mechanisms through which UFAs may exert these
beneficial effects are clearly warranted. Finally, un-
derstanding whether the improvements in CRF
induced by increased UFA consumption result from
improvement in cardiac function or noncardiac fac-
tors, such as favorable changes in body composition
(5), remains a critical question to investigate in future
studies.
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FIGURE 1 Dietary and Plasma Level of UFAs, MUFAs, and PUFAs
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(A) Dietary and plasma level of unsaturated fatty acids (UFAs) (monounsaturated fatty acids [MUFAs], polyunsaturated fatty acids [PUFA]) and (B) changes in peak
oxygen consumption (VO2), exercise time, and O2 pulse.
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